Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLAX study of perioperative flurbiprofen axetil in resectable non-small cell lung cancer
jRCTs031190167Phase 2Active, not recruiting
- Start
- Feb 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of flurbiprofen axetil in non-small cell lung cancer (NSCLC) (2 arms). Primary endpoint: Relapse-free survival. Started Feb 2020; status: active, not recruiting.
02
Drugs
flurbiprofen axetil
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs031190167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031190167.